ATE198271T1 - Syndecan-stimulierung der zellulären differenzierung - Google Patents

Syndecan-stimulierung der zellulären differenzierung

Info

Publication number: ATE198271T1
Authority: AT; Austria
Prior art keywords: syndecan; methods; cellular differentiation; stimulation; cell
Prior art date: 1992-12-01

Application number

AT94900846T

Other languages

English (en)

Inventor

Anni Maija Waerri

Leena Maria Alanen-Kurki

Petri Olli Viljami Auvinen

Panu Mikko Jaakola

Markku Tapani Jalkanen

Sirpa Marianne Leppae

Markku Sakari Mali

Tapani Antero Vihinen

Original Assignee

Biotie Therapies Oy

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-01

Filing date

1993-12-01

Publication date

2001-01-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25534102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE198271(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-12-01 Application filed by Biotie Therapies Oy filed Critical Biotie Therapies Oy

2001-01-15 Application granted granted Critical

2001-01-15 Publication of ATE198271T1 publication Critical patent/ATE198271T1/de

Links

102000019361 Syndecan Human genes 0.000 title abstract 5
108050006774 Syndecan Proteins 0.000 title abstract 5
DIOQZVSQGTUSAI-UHFFFAOYSA-N n-butylhexane Natural products CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 title abstract 5
230000024245 cell differentiation Effects 0.000 title abstract 2
230000000638 stimulation Effects 0.000 title 1
239000003795 chemical substances by application Substances 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
230000003211 malignant effect Effects 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Steroid Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AT94900846T 1992-12-01 1993-12-01 Syndecan-stimulierung der zellulären differenzierung ATE198271T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US98842792A	1992-12-01	1992-12-01
PCT/FI1993/000514 WO1994012162A1 (en)	1992-12-01	1993-12-01	Syndecan stimulation of cellular differentiation

Publications (1)

Publication Number	Publication Date
ATE198271T1 true ATE198271T1 (de)	2001-01-15

Family

ID=25534102

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94900846T ATE198271T1 (de)	1992-12-01	1993-12-01	Syndecan-stimulierung der zellulären differenzierung

Country Status (9)

Country	Link
EP (1)	EP0671909B1 (de)
JP (1)	JPH08503848A (de)
AT (1)	ATE198271T1 (de)
AU (1)	AU687767B2 (de)
CA (1)	CA2150714C (de)
DE (1)	DE69329802T2 (de)
DK (1)	DK0671909T3 (de)
ES (1)	ES2154290T3 (de)
WO (1)	WO1994012162A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5726058A (en) *	1992-12-01	1998-03-10	Jalkanen; Markku	Syndecan stimulation of cellular differentiation
US6017727A (en) *	1994-03-07	2000-01-25	Biotie Therapies Ltd.	Syndecan enhancer element and syndecan stimulation of cellular differentiation
US6492344B1 (en)	1993-12-01	2002-12-10	Biotie Therapies Corp.	Syndecan enhancer element and syndecan stimulation of cellular differentiation
US5851993A (en) *	1994-06-13	1998-12-22	Biotie Therapies Ltd.	Suppression of tumor cell growth by syndecan-1 ectodomain
US6632447B1 (en)	1998-05-07	2003-10-14	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
US6413533B1 (en)	1998-05-07	2002-07-02	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
PT1003496E (pt) *	1998-05-07	2005-04-29	Univ Tennessee Res Corp	Medicamento para tratamento de neoplasia intra-epitelial prostatica
US6410043B1 (en)	1998-05-07	2002-06-25	The University Of Tennessee Research Corporation	Method for chemoprevention of prostate cancer
AU2003203589B2 (en) *	1998-05-07	2005-10-27	The University Of Tennessee Research Corporation	A method for chemoprevention of prostate cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8806893D0 (en) *	1988-03-23	1988-04-27	Unilever Plc	Cosmetic composition
JPH04224522A (ja) *	1990-04-27	1992-08-13	Merck & Co Inc	繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
US5147854A (en) *	1990-05-22	1992-09-15	Hoffmann-La Roche Inc.	Tgf-b compositions and method
AU650936B2 (en) *	1991-01-15	1994-07-07	Oy Biotie Therapies Ltd	Detection of syndecan content in biological materials such as tissues and body fluids for indications of malignant transformations of cells

1993
- 1993-12-01 DK DK94900846T patent/DK0671909T3/da active
- 1993-12-01 AT AT94900846T patent/ATE198271T1/de not_active IP Right Cessation
- 1993-12-01 ES ES94900846T patent/ES2154290T3/es not_active Expired - Lifetime
- 1993-12-01 EP EP94900846A patent/EP0671909B1/de not_active Expired - Lifetime
- 1993-12-01 CA CA002150714A patent/CA2150714C/en not_active Expired - Fee Related
- 1993-12-01 JP JP6512818A patent/JPH08503848A/ja active Pending
- 1993-12-01 AU AU55649/94A patent/AU687767B2/en not_active Ceased
- 1993-12-01 WO PCT/FI1993/000514 patent/WO1994012162A1/en not_active Ceased
- 1993-12-01 DE DE69329802T patent/DE69329802T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69329802D1 (de)	2001-02-01
DE69329802T2 (de)	2001-07-19
WO1994012162A1 (en)	1994-06-09
AU687767B2 (en)	1998-03-05
AU5564994A (en)	1994-06-22
CA2150714A1 (en)	1994-06-09
EP0671909A1 (de)	1995-09-20
ES2154290T3 (es)	2001-04-01
DK0671909T3 (da)	2001-03-19
CA2150714C (en)	2002-02-05
EP0671909B1 (de)	2000-12-27
JPH08503848A (ja)	1996-04-30

Similar Documents

Publication	Publication Date	Title
MX9101913A (es)	1992-07-08	Derivados de quinazolinas para potenciar la actividad antitumoral
DE69720811D1 (de)	2003-05-15	L-Ribavirin und dessen Verwendung
DE3883374D1 (de)	1993-09-23	Acylatiertes uridin und cytidin und deren verwendungen.
DE69533581D1 (de)	2004-11-04	Sprühbare zubereitungen enthaltend dispernierten pulvers sowie dessen anwendungsverfahren
NZ505011A (en)	2004-12-24	Expression vectors and cell lines expressing VEGF-D and method of treating melanomas
ES2167377T3 (es)	2002-05-16	Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
ES2071484T3 (es)	1995-06-16	Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
DE69938871D1 (de)	2008-07-17	Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen
ATE390932T1 (de)	2008-04-15	Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
ATE227717T1 (de)	2002-11-15	3-pyridylenantiomere und ihre verwendung als analgetika
EP0151989A3 (en)	1986-10-08	Means for the treatment of cardiac diseases
DE69710065D1 (de)	2002-03-14	Androsten-derivate
ES2082198T3 (es)	1996-03-16	Inhibidores de esteroide-sulfatasa.
ATE197670T1 (de)	2000-12-15	Parenterales busulfan zur behandlung von malignen krankheiten
DE69631478D1 (de)	2004-03-11	Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE93138T1 (de)	1993-09-15	Verwendung insulin-sensiblisierender wirkstoffe zur behandlung von hypertonie.
ATE34077T1 (de)	1988-05-15	Hautbehandlungsmittel.
ATE217514T1 (de)	2002-06-15	Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
DE69329802D1 (de)	2001-02-01	Syndecan-stimulierung der zellulären differenzierung
DE69535081D1 (de)	2006-08-03	Verwendung von Prostaglandin A oder dessen Derivaten zur Behandlung von Psoriasis
NO994330L (no)	1999-10-25	Metode for behandling av en tumor
DK0637306T3 (da)	2001-07-30	4-Imidomethyl-1-[2'-phenyl-2'-oxoethyl]-piperidiner som serotonin-5HT2-antagonister, deres fremstilling og anvendelse til terapi
ATE80616T1 (de)	1992-10-15	Prostaglandin e1-derivate und ihre therapeutische anwendung.
ES2068714T3 (es)	1995-04-16	Derivados de pirimidina para aumentar la actividad antitumoral.
BG50159A3 (bg)	1992-05-15	Метод за получаване на производни на пиранобензоксадиазол

Legal Events

Date	Code	Title	Description
2003-09-15	REN	Ceased due to non-payment of the annual fee